Page last updated: 2024-11-04

vorinostat and Neoplasm Metastasis

vorinostat has been researched along with Neoplasm Metastasis in 20 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research Excerpts

ExcerptRelevanceReference
"The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer."9.13A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. ( Aparicio, A; Doroshow, JH; Frankel, P; Gandara, DR; Leong, L; Lim, D; Luu, TH; McNamara, M; Morgan, RJ; Portnow, J; Smith, DD; Somlo, G; Wong, C, 2008)
"Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)."7.83Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016)
"The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer."5.13A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. ( Aparicio, A; Doroshow, JH; Frankel, P; Gandara, DR; Leong, L; Lim, D; Luu, TH; McNamara, M; Morgan, RJ; Portnow, J; Smith, DD; Somlo, G; Wong, C, 2008)
"Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)."3.83Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016)
"Vorinostat is a histone deacetylase inhibitor (HDACi)."2.84A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. ( Barrett, MT; Boerner, SA; Casetta, L; Chao, J; Chen, A; Goncalves, PH; Hansen, AR; Heilbrun, LK; Kummar, S; Lenkiewicz, E; LoRusso, PM; Malasi, S; Piekarz, RL; Pilat, MJ; Siu, LL; Smith, DW; Sukari, AW, 2017)
"Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients."2.73Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. ( Blumenschein, GR; Chen, C; Chiao, JH; Frankel, SR; Kies, MS; Kumar, AJ; Lu, C; Papadimitrakopoulou, VA; Ricker, JL, 2008)
"However, the role of Rnd1 in hepatocellular carcinoma (HCC) progression remains unclear."1.48The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. ( Chai, ZT; Jia, QA; Ma, DN; Qin, CD; Ren, ZG; Sun, HC; Tang, ZY; Wang, CH; Zhang, N; Zhang, SZ; Zhu, XD, 2018)
"Metastasis is the reason for most cancer death, and a crucial primary step for cancer metastasis is invasion of the surrounding tissue, which may be initiated by some rare tumor cells that escape the heterogeneous primary tumor."1.43Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. ( Chen, X; Deng, Q; Feng, J; Guo, C; Huang, H; Ma, S; Shen, B; Wu, K; Wu, Z; Xia, B; Zhang, J; Zhang, K; Zhang, S; Zhu, L, 2016)
"Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis."1.42Histone deacetylase inhibitor for NUT midline carcinoma. ( Bell, D; Christensen, AM; Maher, OM; Tarek, N; Yedururi, S, 2015)
"SAHA inhibited tumor progression and metastasis in the murine xenograft model."1.40Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. ( Fujiwara, S; Goshima, F; Imadome, K; Iwata, S; Kanazawa, T; Kimura, H; Murata, T; Nakagawa, H; Siddiquey, MN; Suzuki, M, 2014)
"Using an experimental metastasis mouse model, we further demonstrated that decitabine and vorinostat cooperate to suppress colon carcinoma metastasis."1.38Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. ( Bardhan, K; Liu, K; McGaha, TL; Torres, CM; Yang, D; Zimmerman, M, 2012)
"Progression of prostate cancer following castration is associated with increased androgen receptor (AR) expression and signaling despite AR blockade."1.36Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. ( Coleman, IM; Haugk, K; Mostaghel, EA; Nelson, PS; Nguyen, HM; Page, ST; Plymate, SR; Soriano, K; Sprenger, CC; Sun, H; Sun, S; Vessella, RL, 2010)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (15.00)29.6817
2010's16 (80.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Gray, JE1
Saltos, A1
Tanvetyanon, T1
Haura, EB1
Creelan, B1
Antonia, SJ1
Shafique, M1
Zheng, H1
Dai, W1
Saller, JJ1
Chen, Z1
Tchekmedyian, N1
Goas, K1
Thapa, R1
Boyle, TA1
Chen, DT1
Beg, AA1
Rodriguez, CP1
Wu, QV1
Voutsinas, J1
Fromm, JR1
Jiang, X1
Pillarisetty, VG1
Lee, SM1
Santana-Davila, R1
Goulart, B1
Baik, CS1
Chow, LQM1
Eaton, K1
Martins, R1
Goncalves, PH1
Heilbrun, LK1
Barrett, MT1
Kummar, S1
Hansen, AR1
Siu, LL1
Piekarz, RL1
Sukari, AW1
Chao, J1
Pilat, MJ1
Smith, DW1
Casetta, L1
Boerner, SA1
Chen, A1
Lenkiewicz, E1
Malasi, S1
LoRusso, PM1
Peela, N1
Barrientos, ES1
Truong, D1
Mouneimne, G1
Nikkhah, M1
Li, Q1
Ding, C1
Meng, T1
Lu, W1
Liu, W1
Hao, H1
Cao, L1
Qin, CD1
Ma, DN1
Zhang, SZ1
Zhang, N1
Ren, ZG1
Zhu, XD1
Jia, QA1
Chai, ZT1
Wang, CH1
Sun, HC1
Tang, ZY1
Liu, S1
Li, F1
Pan, L1
Yang, Z1
Shu, Y1
Lv, W1
Dong, P1
Gong, W1
Siddiquey, MN1
Nakagawa, H1
Iwata, S1
Kanazawa, T1
Suzuki, M1
Imadome, K1
Fujiwara, S1
Goshima, F1
Murata, T1
Kimura, H1
Maher, OM1
Christensen, AM1
Yedururi, S1
Bell, D1
Tarek, N1
Mu, X1
Brynien, D1
Weiss, KR1
Patel, S1
Hurez, V1
Nawrocki, ST1
Goros, M1
Michalek, J1
Sarantopoulos, J1
Curiel, T1
Mahalingam, D1
Zhang, S1
Wu, K1
Feng, J1
Wu, Z1
Deng, Q1
Guo, C1
Xia, B1
Zhang, J1
Huang, H1
Zhu, L1
Zhang, K1
Shen, B1
Chen, X1
Ma, S1
Thapa, RK1
Nguyen, HT1
Jeong, JH1
Shin, BS1
Ku, SK1
Choi, HG1
Yong, CS1
Kim, JO1
Woyach, JA1
Kloos, RT1
Ringel, MD1
Arbogast, D1
Collamore, M1
Zwiebel, JA1
Grever, M1
Villalona-Calero, M1
Shah, MH1
Luu, TH1
Morgan, RJ1
Leong, L1
Lim, D1
McNamara, M1
Portnow, J1
Frankel, P1
Smith, DD1
Doroshow, JH1
Wong, C1
Aparicio, A1
Gandara, DR1
Somlo, G1
Krejsgaard, T1
Kopp, K1
Ralfkiaer, E1
Willumsgaard, AE1
Eriksen, KW1
Labuda, T1
Rasmussen, S1
Mathiesen, AM1
Geisler, C1
Lauenborg, B1
Becker, JC1
Zhang, Q1
Wasik, MA1
Odum, N1
Woetmann, A1
Sun, S1
Sprenger, CC1
Vessella, RL1
Haugk, K1
Soriano, K1
Mostaghel, EA1
Page, ST1
Coleman, IM1
Nguyen, HM1
Sun, H1
Nelson, PS1
Plymate, SR1
Wong, NS1
Seah, EZh1
Wang, LZ1
Yeo, WL1
Yap, HL1
Chuah, B1
Lim, YW1
Ang, PC1
Tai, BC1
Lim, R1
Goh, BC1
Lee, SC1
Yang, D1
Torres, CM1
Bardhan, K1
Zimmerman, M1
McGaha, TL1
Liu, K1
Blumenschein, GR1
Kies, MS1
Papadimitrakopoulou, VA1
Lu, C1
Kumar, AJ1
Ricker, JL1
Chiao, JH1
Chen, C1
Frankel, SR1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies[NCT02538510]Phase 1/Phase 250 participants (Actual)Interventional2015-10-08Completed
Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma[NCT00134043]Phase 219 participants (Actual)Interventional2005-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Progression Free Survival

The Kaplan Meier methods will be used to estimate progression free survival. (NCT02538510)
Timeframe: Up to 2 years

InterventionMonths (Mean)
Head and Neck Squamous Cell Carcinoma12.6
Salivary Gland Carcinoma14.0

Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

Toxicities will be summarized as the number and percentage of patients with each type of toxicity, per Criteria for Adverse Events version 4.0 (NCT02538510)
Timeframe: Up to 30 days after the completion of study treatment

,
InterventionParticipants (Count of Participants)
Adrenal insufficiencyALT increaseAnorexiaArthiritisAST increaseCoughIncreased CreatinineDermatitisDiarrheaFever with leukocytosisFatigueHyponatremiaHypothyroidismColitis and IleitisMalaiseNauseaNephritisPneumonitisNeuritisTracheitis/EpiglottitisVomiting
Head and Neck Squamous Cell Carcinoma100001210022111101011
Salivary Gland Carcinoma111110501140000310102

Objective Response Rate

Radiologic assessments of measurable disease will be performed using radiographic imaging. RECIST 1.1 and immune response criteria will be used to assess response to therapy. Responses will be summarized as frequencies and percentages. (NCT02538510)
Timeframe: Up to 2 years

,
InterventionParticipants (Count of Participants)
partial responsestable diseaseprogressive disease
Head and Neck Squamous Cell885
Salivary Gland Carcinoma4136

Objective Response Rate (PR + CR) Using RECIST/WHO Response Criteria

"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR., or similar definition that is accurate and appropriate." (NCT00134043)
Timeframe: Up to 3 years

,
Interventionpercentage of participants (Number)
PR (Partial Response)CR (Complete Response)Stable disease
DTCs (Well-differentiated Thyroid Carcinomas)0056
MTC (Medullary Thyroid Cancer)000

Trials

7 trials available for vorinostat and Neoplasm Metastasis

ArticleYear
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 11-15, Volume: 25, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2019
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 02-15, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2020
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
    Oncotarget, 2017, May-16, Volume: 8, Issue:20

    Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Chromatin Assembly and Disassembly; Exome Sequencing; Female

2017
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Enzy

2009
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Fema

2008
Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
    Pharmacogenetics and genomics, 2011, Volume: 21, Issue:11

    Topics: Adult; Antineoplastic Agents; Asian People; Breast Neoplasms; Demography; Disease-Free Survival; Fem

2011
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
    Investigational new drugs, 2008, Volume: 26, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Capsules; Car

2008

Other Studies

13 other studies available for vorinostat and Neoplasm Metastasis

ArticleYear
Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor-stroma microfluidic model.
    Integrative biology : quantitative biosciences from nano to macro, 2017, Dec-11, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diffusion;

2017
Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner.
    Journal of pharmacological sciences, 2017, Volume: 135, Issue:4

    Topics: Butyrates; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Histone Deacetylase Inhibitors; Hi

2017
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
    Cell death & disease, 2018, 05-01, Volume: 9, Issue:5

    Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Decitabine; Epigenesis, Genet

2018
BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo.
    Cancer science, 2019, Volume: 110, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Divisio

2019
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
    Cancer science, 2014, Volume: 105, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Progres

2014
Histone deacetylase inhibitor for NUT midline carcinoma.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:4

    Topics: Adolescent; Carcinoma; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mandibular

2015
The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.
    BioMed research international, 2015, Volume: 2015

    Topics: Aldehyde Dehydrogenase 1 Family; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prol

2015
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
    Oncotarget, 2016, Sep-13, Volume: 7, Issue:37

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Color

2016
Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
    Oncotarget, 2016, Oct-18, Volume: 7, Issue:42

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cel

2016
Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
    Nanomedicine : nanotechnology, biology, and medicine, 2017, Volume: 13, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomi

2017
A novel xenograft model of cutaneous T-cell lymphoma.
    Experimental dermatology, 2010, Volume: 19, Issue:12

    Topics: Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Transplantation; Disease Models, A

2010
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
    The Journal of clinical investigation, 2010, Volume: 120, Issue:8

    Topics: Androgen Antagonists; Animals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hyd

2010
Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.
    Journal of immunology (Baltimore, Md. : 1950), 2012, May-01, Volume: 188, Issue:9

    Topics: Adaptor Proteins, Signal Transducing; Adoptive Transfer; Animals; Antineoplastic Combined Chemothera

2012